Jason S. Goldfeder, MD, a revered teacher in the Division of Medical Education of the Department of Medicine at the School of Medicine, died Dec. 9, 2015, following a 12-year battle with amyotrophic lateral sclerosis (ALS).
Timothy M. Miller, MD, PhD, a leading researcher in the neurodegenerative disorder amyotrophic lateral sclerosis (ALS), has been named the David Clayson Professor of Neurology at the School of Medicine. The professorship was established in 2001 through a bequest from David Clayson, PhD, to support innovative research into treatments for ALS.
Genetic mutations may cause more cases of amyotrophic lateral sclerosis (ALS) than scientists previously had realized, according to researchers. Shown are study authors Janet Cady, a PhD candidate, and Matthew Harms, MD, assistant professor of neurology at the School of Medicine.
Digoxin, a medication that has been used to treat heart failure, may be adaptable for the treatment of amyotrophic lateral sclerosis (ALS), a progressive, paralyzing disease, suggests new research at the School of Medicine.
An investigational treatment for an inherited form of Lou Gehrig’s disease has passed an early phase clinical trial for safety, researchers at the School of Medicine and Massachusetts General Hospital report. A mutated protein that causes an inherited form of Lou Gehrig’s disease leads to clumps in the human cells, which are pictured.